Company profile: Immuneering
1.1 - Company Overview
Company description
- Provider of bioinformatics-driven drug discovery developing investigational medicines, including IMM-1-104 targeting RAS-mutant advanced solid tumors with once-daily oral dosing, and IMM-6-415, a Deep Cyclic Inhibitor for RAF or RAS-mutant advanced solid tumors with twice-daily dosing; also maintains an Expanded Access Policy (not currently available).
Products and services
- Expanded Access Policy: A formal, investigational-use policy outlining conditions under which patients may receive investigational treatments outside clinical trials, currently unavailable for Immuneering's product candidates.
- IMM-1-104: An investigational drug targeting tumors with RAS mutations, evaluated in advanced solid tumors with once-daily oral dosing for selective impact on cancer cells.
- IMM-6-415: A mutation-targeted Deep Cyclic Inhibitor for advanced solid tumors with RAF or RAS mutations, evaluated for impact on cancer cells with twice-daily oral dosing.
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Immuneering
Palamedrix
HQ: United States
Website
- Description: Provider of a multi-omic platform leveraging DNA nanotechnology to deliver comprehensive data for biomedical applications, accelerating advancements in life science and medicine.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Palamedrix company profile →
Hexagon Bio
HQ: United States
Website
- Description: Provider of data-driven biotech solutions developing targeted small molecule therapeutics, including drug-target prediction via the TICker algorithm to identify microbial secondary metabolites that inhibit cancer-related proteins; DNA sequencing to build the world's largest database of microbial genomes and metabolites; compound production via the HEx platform using heterologous expression; and ADC payloads from natural products for oncology.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Hexagon Bio company profile →
Ingenuity
HQ: United States
Website
- Description: Provider of a software platform and information services that enable enterprise customers to give life science researchers access to information via internal portals, search engines, other software, and workflow sources, allowing them to search, explore, visualize, interpret, and analyze complex biological systems.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Ingenuity company profile →
Curetis
HQ: Germany
Website
- Description: Provider of molecular diagnostic tools for severe infectious diseases, offering the Unyvero Platform with multiplex PCR and broad panels for pathogen and resistance gene detection. Solutions include the integrated Unyvero System (L4 Lysator, C8 Cockpit, A50 Analyzer), application cartridges for syndromic testing, and the Unyvero A50 rapid solution delivering results in less than 5 hours.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Curetis company profile →
Variantyx
HQ: United States
Website
- Description: Provider of molecular diagnostics specializing in advanced genetic testing: PCR-free whole genome sequencing for uniform coverage and detection of clinically relevant variants; IriSight tests for SNVs, indels, structural, repeat expansions, mitochondrial variants; Genomic Intelligence analytical software; OncoAlly tumor profiling using WGS, WES and RNA; and ClaudIA for Genomics producing actionable reports for cancer treatment management.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Variantyx company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Immuneering
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Immuneering
2.2 - Growth funds investing in similar companies to Immuneering
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Immuneering
4.2 - Public trading comparable groups for Immuneering
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →